Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging in Pancreatic Cancer or Other CA19-9 Positive Malignancies
NCT04883775Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVT-2163 in pancreatic cancer (PC) and malignancy, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of subjects with treatment-related adverse events at 1 year and Biodistribution of MVT-2163 at 1 year. Started May 2021; status: completed.
02
Drugs
MVT-2163
03
Conditions
pancreatic cancer (PC)malignancy
Beyond the preview
Go deeper on NCT04883775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883775.